glp-1 and trump The administration announced price cuts for weight-loss drugs Zepbound Wegovy, with direct-to-consumer access via TrumpRX in 2026. #trump #politicsnews #GLP1 What Trump's GLP-1 weight-loss drug

What happens if a clinician determines a consumer is not a candidate for GLP-1 medication

Genes that are involved in detoxifying compounds that we're exposed to from our food, like heterocyclic amines

Additional considerations include: Gastrointestinal effects : Wegovy commonly causes nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation

Technologies such as electronic clinical outcomes assessment are widely adopted but still evolving

Reduced hunger, delayed gastric emptying, and persistent fullness can make it difficult to consume adequate energy for exercise, potentially compromising performance and muscle preservation